Canada markets close in 2 hours 27 minutes

Nexalin Technology, Inc. (NXL)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.3750-0.0450 (-3.17%)
As of 01:16PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous Close1.4200
Open1.3800
Bid1.3300 x 100
Ask1.4600 x 100
Day's Range1.3500 - 1.4600
52 Week Range0.2530 - 3.4000
Volume35,338
Avg. Volume822,503
Market Cap10.225M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.6300
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Nexalin Technology Regains Compliance with Nasdaq Continued Listing Requirements

    HOUSTON, TEXAS, April 25, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) announced that the Company received notice from The Nasdaq Stock Market (“Nasdaq”) on April 23, 2024, notifying the Company that it has regained compliance with Nasdaq’s minimum bid price requirement under Nasdaq Rule 5550(a)(2). Mark White, CEO of Nexalin, stated, “We remain committed to our mission of revolutionizing the treatment of mental health and neurological condi

  • GlobeNewswire

    Nexalin Technology CEO Provides Letter to Shareholders

    Reports on growing clinical data supporting its neurostimulation technology and progress advancing its new Gen-3 HALO™ Clarity Virtual Clinic modelHOUSTON, April 10, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today provided the following letter to shareholders from the Company’s CEO, Mark White, including updates regarding the growing clinical data supporting its non-invasive, frequency-based deep brain stimulation device, as well as, prog

  • GlobeNewswire

    Nexalin Technology Accelerates Manufacturing of its HALO™ Clarity Following Successful Usability, Feasibility, and Electrical Testing

    The new Gen-3 HALO™ Clarity 15 milliamp (mA) The new Gen-3 HALO™ Clarity 15 milliamp (mA) The new Gen-3 HALO™ Clarity 15 milliamp (mA) HOUSTON, TX, April 09, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today announced it has completed the first full production test run and successfully performed usability, feasibility design verification, and electrical safety testing for its new Gen-3 HALO™ Clarity 15 milliamp (mA) neurostimulation device